In the days leading up to the pap testing for cervical cancer, health officials in the U.S. and elsewhere were scrambling to identify the best ways to gather accurate information about the results, in order to ensure that the public was aware of the possible health risks and to avoid any false alerts.
The new Pap test paper has been approved by the U,S.
Food and Drug Administration, which means it will be distributed to patients in hospitals in the United States.
On Tuesday, it was approved for use in a clinical trial for a cervical cancer screening test called the Pap test rapportivi.
It was created in 2005 to identify patients with cervical cancer in which there are symptoms that could indicate the presence of the disease.
To be approved, the paper must be submitted for approval to the U.,S.
National Institutes of Health, which will review the study to ensure it meets their standards for scientific accuracy.
Dr. Susan T. Kaptchuk, the chief medical officer of the U of T Health Sciences Center, said the paper, which is already being distributed to some patients, is the first test paper approved by NIH for clinical use.
“This is a milestone that has never been achieved in clinical testing and that will make this testing a standard,” she said.
The Pap test is currently used in about 500,000 women and in more than 60 countries.
But the NIH, through the Centers for Disease Control and Prevention, has also been using it to screen women for cervical dysplasia, or a condition in which the cervix becomes smaller and smaller, which may lead to an abnormal pap test result.
Some women with abnormal Pap tests have had a high risk of cancer.
“I think this paper is important, because the Pap tests are very sensitive,” Dr. TKaptchuk said.
“So we are very hopeful that this paper will make the difference between screening women who have a high chance of having cervical cancer and people who have normal Pap tests.”
The Pap tests for cervical cancers are usually done using a needle and syringe and can take several days to run through a lab, so the FDA expects to see results in about six to eight weeks.
However, Dr. Kafka said the Pap testing process is more sensitive and the time frame may be shorter.
She said the FDA and the NIH are hopeful that the new Pap testing paper will help reduce the number of false positives.
In the past, a false positive was much more common.
“We’re now seeing fewer than 50 per cent of cervical cancers that are missed by screening,” she explained.
“The pap test is very sensitive and we need to do everything we can to make it as accurate as possible.”